Celltrion USA has signed a contract with Ventegra® to add Yuflyma® (adalimumab-aaty) as a preferred formulary product in both public and private insurance markets – By inclusion in Ventegra’s formularies, Yuflyma® has secured access through the appropriate channel for about 3.6% of the U.S. population October 05, 2023 04:52 PM Eastern Daylight Time JERSEY CITY, N.J.–(BUSINESS WIRE)–Celltrion USA has […]
Celltrion USA launches Yuflyma® (adalimumab-aaty), a Humira® (adalimumab) biosimilar, in the United States Yuflyma is Celltrion USA’s high-concentration (100mg/mL) and citrate-free formulation of Humira® (adalimumab) biosimilar JERSEY CITY, N.J.–Celltrion USA today announced the launch of Yuflyma® (adalimumab-aaty), a high-concentration (100mg/mL) and citrate-free formulation of Humira® (adalimumab) biosimilar, providing an alternative option for patients. Yuflyma is indicated […]
Celltrion USA Announces U.S. FDA Approval of Yuflyma® (adalimumab-aaty), a High-Concentration and Citrate-Free Formulation of Humira® (adalimumab) Biosimilar Yuflyma is FDA approved to treat eight conditions including Crohn’s disease and ulcerative colitis Yuflyma is the first high-concentration and citrate-free adalimumab biosimilar to gain EU marketing authorization Yuflyma offers citrate-free and high-concentration adalimumab formulation, providing an alternative treatment […]
Celltrion USA Appoints Thomas Nusbickel as Chief Commercial Officer Seasoned commercial operations executive brings three decades of global biopharmaceutical industry experience to Celltrion USA’s leadership team February 06, 2023, CHICAGO, IL –Celltrion USA, a global leader in expanding access to innovative biologics, today announced the appointment of Thomas Nusbickel as Chief Commercial Officer. Mr. Nusbickel will oversee […]
Celltrion USA announces submission of the Biologics License Application (BLA) of novel subcutaneous formulation of CT-P13 to U.S. Food and Drug Administration CT-P13 SC is a novel subcutaneous formulation of infliximab The Biologics License Application (BLA) submission is based on phase III pivotal data that evaluated the efficacy and safety of CT-P13 SC […]
Celltrion USA Receives U.S. FDA Approval for its Oncology Biosimilar Vegzelma® (bevacizumab-adcd) for the Treatment of Six Types of Cancer Vegzelma® is Celltrion’s third oncology biosimilar to receive approval from the U.S. FDA Vegzelma® offers U.S. patients living with multiple types of cancer a new, safe, and effective treatment option The approval is based on totality of evidence […]